Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Terminated

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Imatinib

First Posted Date: 2014-05-26

Last Posted Date: 2016-09-07

Lead Sponsor: Kerman University of Medical Sciences

Target Recruit Count: 170

Registration Number: NCT02146846

Locations: 🇮🇷
Shahid-Bahonar hospital, Kerman, Iran, Islamic Republic of

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 3

Completed

Conditions: Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

Interventions: Drug: Imatinib
Drug: Bosutinib

First Posted Date: 2014-05-05

Last Posted Date: 2021-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 536

Registration Number: NCT02130557

Locations: 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

and more 179 locations

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1

Completed

Conditions: Chronic Myelogenous Leukemia
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Interventions: Drug: Asciminib (ABL001)
Drug: Nilotinib
Drug: Imatinib
Drug: Dasatinib

First Posted Date: 2014-03-07

Last Posted Date: 2024-03-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 326

Registration Number: NCT02081378

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering, New York, New York, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸
Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, United States

and more 4 locations

A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study

Not Applicable

Conditions: Gastrointestinal Cancers

Interventions: Drug: Sorafenib or Sunitinib
Drug: Vandetanib
Drug: Erlotinib or Gefitinib
Drug: Everolimus
Drug: Imatinib

First Posted Date: 2013-12-17

Last Posted Date: 2016-08-30

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT02013089

Locations: 🇨🇳
Gastrointestinal Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia

Phase 2

Conditions: Chronic Myeloid Leukaemia

Interventions: Drug: Imatinib
Drug: nilotinib
Drug: dasatinib

First Posted Date: 2013-03-05

Last Posted Date: 2017-05-04

Lead Sponsor: University of Liverpool

Target Recruit Count: 168

Registration Number: NCT01804985

Locations: 🇬🇧
University of Liveprool, Liverpool, United Kingdom

A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma

Phase 2

Conditions: Melanoma

Interventions: Drug: imatinib
Drug: Interferon

First Posted Date: 2013-02-04

Last Posted Date: 2013-02-04

Lead Sponsor: Peking University Cancer Hospital & Institute

Target Recruit Count: 40

Registration Number: NCT01782508

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Phase 2

Completed

Conditions: Neurofibromatosis

Interventions: Drug: Gleevec

First Posted Date: 2012-08-27

Last Posted Date: 2016-04-06

Lead Sponsor: Indiana University

Target Recruit Count: 36

Registration Number: NCT01673009

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

Phase 2

Completed

Conditions: Chronic Phase Chronic Myeloid Leukemia

Interventions: Drug: Imatinib
Drug: Dasatinib

First Posted Date: 2012-05-08

Last Posted Date: 2023-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 262

Registration Number: NCT01593254

Locations: 🇺🇸
Northern Indiana Cancer Research Consortium, Crown Point, Indiana, United States
🇺🇸
Local Institution - 0006, Fontana, California, United States
🇮🇹
Local Institution - 0021, Roma, Italy

and more 84 locations